-
2024-516253-49-01
4
2025-12-12
advanced/metastatic HER2-positive breast carcinoma
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521707-48-00
1
2025-11-26
KRAS Altered Advanced or Metastatic Solid Tumors
-
2025-521315-39-00
1
2025-11-05
Axial spondyloarthritis
-
2024-516188-10-00
6
2025-10-07
Intracerebral haemorrhage
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2022-501867-42-01
9
2025-09-08
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2022-501866-22-00
9
2025-08-26
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2025-520557-36-00
1
2025-07-24
Advanced Solid Tumors
-
2024-516616-24-00
5
2025-07-23
Acromegaly
-
2025-521305-40-00
1
2025-07-22
Participants with Advanced Solid Tumors
-
2024-516525-31-01
5
2025-07-14
Primary Biliary Cholangitis
-
2024-517032-22-00
5
2025-06-10
Immune system diseases.
-
2023-509370-39-00
5
2025-06-03
connective tissue diseases
-
2024-515706-77-00
5
2025-05-08
Moderate to Severe Plaque Psoriasis
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2023-508015-23-00
5
2025-04-11
Ovarian cancer recurrent
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-515506-11-00
4
2025-03-24
Urothelial Carcinoma
-
2023-505252-21-00
4
2025-02-14
Hyperkalemia
-
2023-503630-44-00
10
2024-11-20
Treatment of moderate-to-severe Atopic dermatitis